### STORY 1 — PRIORITY #1
Daraxonrasib Pancreatic Cancer Trial Reports 13.2-Month Median Survival
For people with metastatic pancreatic cancer whose disease has progressed after earlier treatment, a once-daily pill is being tested against standard chemotherapy. In the Phase 3 RASolute 302 trial, patients who received daraxonrasib had a median overall survival of 13.2 months, compared with 6.7 months for patients assigned chemotherapy. The results apply to previously treated metastatic disease; they do not show a cure.
Revolution Medicines reported results from 500 people in RASolute 302. The randomized trial compared daily oral daraxonrasib with doctors’ choice of chemotherapy after prior treatment. The company reported a hazard ratio of 0.40 for overall survival, meaning the trial estimated a 60% lower rate of death over the study period in the daraxonrasib group. Median progression-free survival was 7.2 months with the drug and 3.6 months with chemotherapy in the overall study population. Tumors shrank enough to meet the trial’s response measure in 31.6% of patients receiving daraxonrasib, versus 11.2% receiving chemotherapy.
For patients and families, the next step is a conversation with the treating oncologist about the trial population, treatment history, and current access. These results concern metastatic pancreatic ductal adenocarcinoma after earlier therapy. The trial’s findings do not establish that every pancreatic tumor will respond, or that a patient can obtain the drug outside a clinical or regulatory pathway. Ask whether a tumor’s molecular testing and the person’s treatment history match a relevant study or approved use.
Daraxonrasib is an oral RAS(ON) inhibitor: it targets active forms of RAS proteins, which can drive cancer growth. RASolute 302 enrolled patients with documented RAS mutations (predominantly codon 12), with secondary stratifications for wild-type and other RAS variants. The company’s subgroup analysis reported survival benefit across evaluated RAS profiles, but subgroup results do not guarantee benefit for an individual patient. “Median” survival is the point at which half the patients in a group were still alive and half had died; it is not a prediction of how long any one person will live.
The central distinction is fda-accelerated-approval-cancer-drugs/”>treatment setting. RASolute 302 studied daraxonrasib as a later-line, single-agent treatment for metastatic disease. Separate early-stage research is testing it with chemotherapy as a potential first-line combination. Those studies answer different questions and their response percentages should not be treated as interchangeable. The single-agent trial’s overall response rate was 31.6%; a separate Phase 1/2 combination study reported a 60.7% response rate in its first-line cohort. The latter was not a Phase 3 comparison.
The results show a substantial difference in median survival within this trial, while leaving practical questions for doctors and regulators: who should receive the drug, how it compares across treatment histories, and how side effects should be managed. The sponsor described the safety profile as manageable. A patient should review the current prescribing or trial information with an oncology team rather than rely on trial averages to make treatment decisions.
What is daraxonrasib and how does it work?
Daraxonrasib, also called RMC-6236 (brand name Rasonque), is a once-daily oral medicine designed to inhibit active RAS proteins involved in cancer-cell growth. The dosing regimen evaluated in RASolute 302 was 300 mg orally once daily. In the Phase 3 RASolute 302 trial, it was tested in previously treated metastatic pancreatic cancer. The reported survival results do not mean the drug cures pancreatic cancer or is suitable for every patient.
Revolution Medicines said it would submit RASolute 302 data to regulators. The trial result is a clinical finding, not by itself proof of broad commercial availability. Patients should ask their oncologist about current regulatory status, eligibility, and trial options. Further updates will depend on regulatory review and additional studies, including research in earlier treatment settings.